REG-4basebio Plc: Completion of Strategic Investment
12/11/2024 07:15
This Announcement contains inside information for the purposes of Article 7
of the Market Abuse Regulation No. 596/2014 as retained as part of UK law by
virtue of the European Union (Withdrawal) Act 2018 as amended ("EUWA") and
as it may be modified from time to time by or under domestic law including,
but not limited to, by the Market Abuse (Amendment) (EU Exit) Regulations
2019/310). Upon the publication of this Announcement, this inside information
is now considered to be in the public domain.
12 November 2024
4basebio PLC
("4basebio" or the "Company")
Completion of Strategic Investment
Director Dealing, Issue of Equity and Admission to Trading
Directorate Changes
12 November 2024 - 4basebio PLC (AIM: 4BB) (“4basebio” or the
“Company”), which develops and commercialises the large scale manufacture
of synthetic DNA as well as nanoparticle delivery solutions, announces the
completion of the Strategic Investment following receipt of regulatory
approval and clearance under the National Security and Investment Act 2021,
for the investment by (i) Fort Aggregator LP, acting by its general partner,
Elevage Medical Technologies (“Elevage”), a Patient Square Capital
platform and (ii) The Prudential Assurance Company Limited acting by its
investment manager M&G Investment Management Limited (“M&G”), initially
announced on 29 July 2024 (the “Strategic Investment”).
As announced on 9 September 2024, the Strategic Investment is for a combined
amount of £40.0 million through an issuance (the “Issuance”) of ordinary
shares of €1 each (“Ordinary Shares”) in the Company at an issue price
of 1,500 pence per Ordinary Share (the “Issue Price”) (the “Issuance
Shares”) and the purchase of Ordinary Shares from an entity belonging to the
Deutsche Balaton Group and certain directors of the Company (“Sale
Shares”), at a purchase price per Sale Share equal to the Issue Price for an
aggregate purchase price of approximately £29.4 million (the “Secondary
Sale”).
Admission to AIM
Application has been made for the 2,666,667 Issuance Shares to be admitted to
trading on AIM ("Admission"). It is expected that Admission will become
effective at 8.00 a.m. on or around 13 November 2024. The Issuance Shares will
be issued credited as fully paid and will rank in full for all dividends and
other distributions declared, made or paid after Admission and will otherwise
rank on Admission pari passu in all respects with the existing Ordinary
Shares.
Total Voting Rights
Following Admission, the total number of Ordinary Shares in issue will be
15,477,395. The Company does not hold any ordinary shares in treasury.
Therefore, the total number of Ordinary Shares with voting rights will be
15,477,395. This figure may be used by shareholders in the Company as the
denominator for the calculations by which they will determine if they are
required to notify their interest in, or a change to their interest in, the
share capital of the Company under the Financial Conduct Authority's
Disclosure and Transparency Rules.
Secondary Sale
Elevage and M&G have agreed to purchase 1,961,074 Sale Shares in aggregate
and, following the completion of the Issuance and the Secondary Sale, Elevage
and M&G will together hold 4,627,741 Ordinary Shares representing 29.9% of the
Company’s enlarged issued share capital.
Completion of the Secondary Sale is expected to take effect contemporaneously
with Admission.
The resultant significant shareholdings in the Company, following completion
of the Issuance and the Secondary Sale are set out below:
Name Previous holding Previous percentage holding of issued share capital Resultant holding Resultant percentage holding of enlarged issued share capital on Admission
Elevage and M&G(1) - - 4,627,741 29.90%
2Invest AG(2) 3,665,242 28.61% 2,229,083 14.40%
Sparta Invest AG(2) 1,351,718 10.55% 1,351,718 8.73%
Heikki Lanckriet(3) 1,418,994 11.08% 1,103,288 7.13%
Latonba AG(2) 752,030 5.87% 752,030 4.72%
Delphi Unternehmensberatung AG(2) 638,436 4.98% 638,436 4.12%
Franciscus De Busschere 537,255 4.19% 537,255 3.47%
1. On Admission, 2,666,667 Ordinary Shares will be held by Elevage and
1,961,074 Ordinary Shares will be held by M&G.
2. Members or associates of the Deutsche Balaton Group, which is under the
ultimate control of Wilhelm K.T. Zours and will on Admission hold in aggregate
32.43% of the Company’s enlarged issued share capital.
3. Aggregate shareholding of Dr. Heikki Lanckriet and persons closely
associated with him.
Director Appointment and Board Changes
As previously announced, pursuant to the terms of the new Relationship
Agreement, both Elevage and 2Invest AG (“2Invest”) (acting on behalf of
itself and its wider group, the Deutsche Balaton Group) were granted board
appointment rights.
Accordingly, the Company announces the appointment (effective on Admission) of
three Non-executive Directors to the Board of the Company, being; Dr.
Michael Jason Wasserman, appointed on behalf of Elevage (with Elevage
retaining the right to appoint a further director); Mr. Christian Alexander
Ansgar Link (“Alexander”) and Mr. Hansjörg Plaggemars (who previously
served on the Board of the Company from 2020 to 2024), appointed on behalf of
2Invest, with an Independent Non-executive Director expected to join the Board
in due course. Under the terms of the new Relationship Agreement, Elevage has
the right to nominate one of their appointees to be the Chair of the Board.
Further details of any such appointment shall be announced at the relevant
time.
Mr. Joseph Manuel Fernandez and Ms. Maria del Pilar de la Huerta Martinez will
be stepping down from their positions as Non-executive Directors of the
Company, with effect from Admission. The Board of the Company would like to
thank them both for their ongoing advice and support over the years.
Dr. Michael Jason Wasserman, Non-executive Director
Dr. Wasserman, Ph.D., is a Partner and COO of Elevage Medical Technologies,
with over 30 years of experience in healthcare as a scientist, entrepreneur,
executive, and investor. Previously, he served as Managing Partner of Maverix
Private Equity (2021-2023) and spent 17 years at H.I.G. Capital, where he was
Managing Director of the BioHealth platform, overseeing a diverse healthcare
investment portfolio across stages and sectors.
Throughout his career, Dr. Wasserman has actively supported growth-stage
healthcare companies in areas such as R&D, product development, market access,
commercial and corporate strategy, financing, and strategic exits. He has
served on the boards of several companies, including HyperBranch Medical
Technologies (acquired by Stryker), NeuWave Medical (acquired by Johnson &
Johnson), and VertiFlex (acquired by Boston Scientific). Additionally, he has
founded, led, and sold multiple private healthcare ventures.
Dr. Wasserman is a dedicated board member, currently serving on the Board of
Trustees for the Holland Bloorview Kids Rehabilitation Hospital, where he has
been a Trustee since 2020. He also sits on the boards of Toronto Innovation
Acceleration Partners (TIAP), where he chairs the Investment Committee, ORT
Canada, and the Faculty of Science Advisory Board at McGill University. Since
2024, he has been a Director at Nuclera Ltd and Moximed Inc.
Earlier in his career, Dr. Wasserman worked in corporate finance,
pharmaceuticals, and clinical research. He co-founded CELLutions Biosystems in
2004, where he served as a Director. He holds a B.Sc. in Physiology and
Business Administration from McGill University and a Ph.D. in Pharmacology and
Neuroscience from the University of Toronto.
Mr. Alexander Link, Non-executive Director
Mr. Link has extensive experience in banking and management consulting, with a
strong background in finance, risk management, restructuring, portfolio
management, and mergers and acquisitions. He has successfully established,
managed, and restructured operations across Germany, Europe, and Asia.
Currently, Mr. Link is a Director and CFO at Deutsche Balaton AG (since 2020)
and serves on the boards of several of its subsidiaries. Previously, he held
senior roles at Commerzbank and Hypothekenbank Frankfurt from (2004-2019)
Prior to this, he worked as a management consultant at Booz Allen Hamilton
(2001-2004).
Mr. Link earned a law degree from the Albert Ludwig University of Freiburg in
2000 and was admitted to the Frankfurt Bar in 2005.
Mr. Hansjörg Plaggemars, Non-executive Director
Mr. Plaggemars is an independent consultant and has been the Managing Director
of a number of companies, including 2invest AG, since December 2020, and
Delphi Unternehmensberatung AG since December 2023. He has run the consulting
firm Value Consult since 2017.
Amongst his projects, Mr Plaggemars also sits on a number of boards as
non-executive director or supervisory member, including several listed and
private companies, such as Biofrontera AG, GeoPacific Resources Ltd, Altech
Chemicals Limited and Patronus Resources Ltd.
Mr. Plaggemars holds a degree in Business Administration from the University
of Bamberg.
Further information on the newly appointed Non-executive Directors pertaining
to Schedule 2(g) of the AIM Rules for Companies can be found in the Appendix
at the end of this announcement.
Dr. Heikki Lanckriet, CEO and CSO, 4basebio, said: "We are pleased that
Elevage Medical Technologies, a Patient Square Capital platform and
Prudential Assurance Company Limited acting by its investment manager M&G
Investment Management Limited are about to become shareholders in the
Company. Their funding, support and experience will continue to drive the
growth and success of 4basebio. We see this as a significant step in
becoming the leader in the supply of DNA for cell & gene therapies and
vaccines.”
Michael Wasserman, Partner and COO of Elevage Medical Technologies, said:
“Elevage is thrilled to be partnering with the 4basebio management team and
board to advance the company's novel design and manufacture of synthetic DNA,
which have demonstrated novel and highly sought-after characteristics in a
variety of critical applications across the life sciences industry. This
transaction demonstrates Elevage’s commitment to funding innovative life
sciences tools companies.”
M&G Portfolio Manager, Jeremy Punnett, said: "We are delighted to be backing
such an innovative UK company and look forward to supporting its future growth
as it grows internationally. We believe synthetic DNA offers major advantages
over plasmid DNA and will ultimately enhance both the cost effectiveness and
clinical efficacy across a broad range of viral vectors and vaccines.”
Capitalised terms used in this announcement shall, unless otherwise defined,
have the same meanings as set out in the Company’s announcements of 29 July
2024 and 9 September 2024.
Enquiries
4basebio PLC Dr. Heikki Lanckriet +44 (0)1223 967 943
Elevage Medical Technologies Doug Allen (Dukas Linden Public Relations) +1 (646) 722 6530
Sole Placement Agent RBC Capital Markets Rupert Walford / Max Avison / Kathryn Deegan +44 (0)20 7653 4000
Nominated Adviser Cairn Financial Advisers LLP Jo Turner / Sandy Jamieson / Ed Downes +44 (0)20 7213 0880
Broker Cavendish Capital Markets Limited Geoff Nash / Nigel Birks +44 (0)20 7220 0500
Notes to Editors
About 4basebio
4basebio (AIM: 4BB) is an innovation driven life biotechnology company focused
on accelerating the development of advanced therapy medicinal products (ATMPs)
through its high-performance synthetic DNA products and non-viral, cell
targeting nucleic acid delivery platform. The Company’s objective is to
become a market leader in the manufacture and supply of high-quality synthetic
DNA products for research, therapeutic and pharmacological use as well as
development of target specific non-viral vectors for the efficient delivery of
payloads in patients.
About Elevage Medical Technologies
Elevage Medical Technologies is a platform established by Patient Square
Capital and is dedicated to supporting medical technology companies that can
meaningfully improve health outcomes and quality of life for
patients. Elevage provides capital along with deep technical, regulatory, and
operational expertise to companies ranging from advanced clinical development
to commercial acceleration stage. Elevage supports rapidly growing, highly
differentiated companies with paradigm shifting technologies and strives to
help build industry leading medical technologies. To learn more about Elevage,
please visit www.elevagemedical.com.
About M&G Investments
The capital for this deal has been provided by M&G’s Crossover strategy
(Crossover) on behalf of the £129 billion Prudential With Profits Fund.
Crossover is a global strategy led by M&G’s public equity investment
division which provides patient growth equity to high-quality, fast-growing
companies.
M&G Investments is part of M&G plc, a savings and investment business which
was formed in 2017 through the merger of Prudential plc’s UK and Europe
savings and insurance operation and M&G, its wholly owned international
investment manager. M&G plc listed as an independent company on the London
Stock Exchange in October 2019 and has £343.5 billion of assets under
management (as at 31 December 2023). M&G plc has customers in the UK, Europe,
the Americas and Asia, including individual savers and investors, life
insurance policy holders and pension scheme members. For nearly nine decades
M&G Investments has been helping its customers to prosper by putting
investments to work, which in turn creates jobs, homes and vital
infrastructure in the real economy. Its investment solutions span equities,
fixed income, multi asset, cash, private debt, infrastructure and real estate.
M&G recognises the importance of responsible investing and is a signatory to
the United Nations Principles for Responsible Investment (UNPRI) and is a
member of the Climate Bonds Initiative Partners Programme. M&G plc has
committed to achieve net zero carbon emissions on its total book of assets
under management and administration by 2050 and committed to reduce
operational carbon emissions as a corporate entity to net zero by 2030. For
more information, please visit: https://global.mandg.com/.
Forward-looking statements
This Announcement may contain certain statements about the future outlook for
4basebio. Although the directors believe their expectations are based on
reasonable assumptions, any statements about future outlook may be influenced
by factors that could cause actual outcomes and results to be materially
different.
Additional Information
RBC is acting as sole placement agent to the Company in connection with the
Transaction and will not regard any other person as a client in relation to
the Transaction. RBC will not be responsible to any other person for providing
the protections afforded to its clients or for advising any person in relation
to the Transaction or any arrangement referred to in this document.
This Announcement is made for information purposes only and does not
constitute an offer to sell or issue or solicitation to buy, subscribe for or
otherwise acquire shares in 4basebio PLC in any jurisdiction in which any such
offer or solicitation would be unlawful.
The securities discussed herein are not and will not be registered under the
US Securities Act of 1933, as amended (the "Securities Act"), and may not be
offered or sold in the United States, unless registered under the Securities
Act, or pursuant to an exemption from, or in a transaction not subject to,
registration under the Securities Act. No public offering of the securities
discussed herein is being made in the United States and the information
contained herein does not constitute an offering of securities for sale in the
United States and the Company does not currently intend to register any
securities under the Securities Act.
Appendices
Appendix 1 – Schedule 2(g) Disclosures
Mr. Michael Jason Wasserman
Pursuant to Rule 17 and Schedule 2(g) of the AIM Rules for Companies, the
following information is disclosed in respect of Mr. Michael Jason Wasserman
(aged 50):
Current Directorships Previous Directorships held in the past five years
UK USA
Nuclera Ltd Agora Brands LLC
Children's Grief Network Inc
USA On Target Laboratories, Inc
Elevage Medical Technologies, LP Orbus Therapeutics, Inc
Moximed, Inc VertiFlex, Inc
Zerigo Health Inc
Canada
Holland Bloorview Kids Rehabilitation Hospital
ORT Canada
Toronto Innovation Acceleration Partners
Mr. Wasserman holds no Ordinary Shares, and no options or warrants over
Ordinary Shares. There is no further information regarding Mr. Wasserman
that is required to be disclosed under the AIM Rules.
Mr. Christian Alexander Ansgar Link
Pursuant to Rule 17 and Schedule 2(g) of the AIM Rules for Companies, the
following information is disclosed in respect of Mr. Christian Alexander
Ansgar Link (aged 53):
Current Directorships Previous Directorships held in the past five years
Germany Germany
Biofrontera AG* 2invest AG*
bioXXmed AG* Cornerstone Capital Beteiligungen GmbH
CARUS AG* HW Verwaltungs AG*
Deutsche Balaton AG*
DIO Deutsche Immobilien Opportunitäten AG*
Epigenomics AG*
MISTRAL Media AG*
Nordic SSW 1000 Verwaltungs AG*
SPK Süddeutsche Privatkapital AG*
Poland
Nestmedic SA
* Indicates a position held on the Supervisory Board of the company
Mr. Link holds 1,833 Ordinary Shares, equating to approximately 0.01 per cent.
of the Company’s enlarged issued share capital on Admission, and no options
or warrants over Ordinary Shares. There is no further information regarding
Mr. Link that is required to be disclosed under the AIM Rules.
Mr. Hansjörg Plaggemars
Pursuant to Rule 17 and Schedule 2(g) of the AIM Rules for Companies, the
following information is disclosed in respect of Mr. Plaggemars (aged 54):
Current Directorships Previous Directorships held in the past five years
Germany Germany
2invest AG Carus AG*
Alpha Cleantec AG Deutsche Balaton Immobilien I AG*
Altech Advanced Materials AG HW Verwaltungs AG*
Balaton Agro Invest AG Ming Le Sports AG
Biofrontera AG* BCT bio cleantec AG
Delphi Unternehmensberatung AG Biofrontera AG
Epigenomics AG Decheng Technology AG
Heidelberger Beteiligungsholding AG Enapter AG
Strawtec Group AG KlickOwn AG
YVAL Idiosynkratische Investments SE MARNA Beteiligungen AG
Ming Le Sports AG
Australia Nordic SSW 1000 Verwaltungs AG*
Altech Chemicals Limited* OOC CTV Verwaltungs GmbH
GeoPacific Resources Ltd* The Grounds Real Estate Development AG*
Patronus Resources Ltd*
Wiluna Mining Corporation* Australia
Azure Minerals Limited*
PNX Metals Limited*
South Harz Potash Limited*
Spartan Resources Limited*
UK
4basebio plc
* Indicates a position held on the Supervisory Board of the company
Mr Plaggemars was appointed to the board of KAMPA AG, one of Europe’s
leading prefabricated house manufactures, as Chief Restructuring Officer and
Chief Financial Officer in January 2009. Due to the financial position of the
company and excessive liabilities owned to third parties, Mr Plaggemars filed
for insolvency a few weeks after his appointment. The liabilities owed to
third parties were approximately EUR 30 million.
The Cologne Local Court appointed Mr. Plaggemars as a member of the
Supervisory Board of Youbisheng Green Paper AG by resolution dated 22 April
2015, following the opening of preliminary insolvency proceedings against the
Company’s assets on 13 August 2018. In his function as a member of the
Supervisory Board, Mr. Plaggemars assisted in the preparation and
implementation of an insolvency plan. The insolvency plan was filed with the
competent court on 17 October 2017, approved by the creditors on 24 November
2017 and became legally binding on 15 January 2018. The insolvency was
cancelled by court order on 22 February 2018. Creditors as at 30 June 2015
were approximately EUR 1.5 million.
In April 2015, Mr Plaggemars was appointed to the supervisory board of
Ultrasonic AG, by exercise of an appointment right of DELPHI
Unternehmensberatung AG after the company filed for insolvency on 11 March
2015. Ultrasonic AG was guarantor under a bank credit facility to Cathay
United Bank for an amount of US$60 million. The company was dissolved by the
opening of insolvency proceedings against its assets on 10 August 2016.
In December 2017, Mr. Plaggemars was appointed to the management board of S&O
Beteiligungen AG (formerly S&O Agrar AG). Insolvency proceedings for S&O Agrar
AG had been opened on 2 August 2016. Mr. Plaggemars was appointed to the
management board of the former S&O Agrar AG in order to rescue the company
within the framework of an insolvency plan. The insolvency plan was filed with
the competent courts on 19 November 2018, approved by the creditors on 17
January 2019 and by the competent courts on 10 May 2019. The insolvency
proceedings were terminated by court order on 14 June 2019.
In January 2018, Mr. Plaggemars was a member of the supervisory board of
Biofrontera AG and was also on the management board of DELPHI
Unternehmensberatung AG (“DELPHI”). At the request of the Regional Court
of Cologne (Landgericht), Mr. Plaggemars had submitted in November 2018 a
written statement in his capacity as member of the supervisory board of
Biofrontera AG in a proceeding pending at the court in which DELPHI
Unternehmensberatung AG (“DELPHI”) had applied for the appointment of a
special auditor pursuant to Section 142 (2) AktG. In January 2019, the
supervisory board of Biofrontera AG filed an application with the Cologne
Local Court for Mr Plaggemars to be removed from its supervisory board on the
grounds that solely the supervisory board of Biofrontera AG would have been
authorised to issue a statement in November 2018. The application was upheld
and consequently Mr Plaggemars was dismissed as a member of the supervisory
board of Biofrontera AG in March 2019. In August 2024 Mr. Plaggemars was
reappointed as a Supervisory Board Member of Biofrontera AG.
On 5 September 2018, Mr. Plaggemars was appointed to the management board of
Snowbird AG following which a review was undertaken by the management board of
the economic situation of the company, in particular the assets and
liabilities of the company. The management board determined that the company
was insolvent and over-indebted and therefore filed for insolvency on 10
October 2018. The insolvency proceedings were opened by court order on 1
January 2019. The aim was to save the company by implementing an insolvency
plan, but due to a major creditor voting against the insolvency plan, it could
not be implemented and the company is currently being wound up by the
insolvency administrator.
Mr. Plaggemars was appointed to the management board of Decheng Technology AG
on 10 April 2019 with effect of 2 May 2019, following which a review was
undertaken by the management board of the economic situation of the company,
in particular the assets and liabilities of the company. The management board
determined that the company was insolvent and over-indebted and therefore
filed for insolvency on 27 May 2019. The insolvency proceedings were opened by
court order on 10 October 2019. The aim is to rescue the company by
implementing an insolvency plan, which has been approved by the creditor
committee on 14 October 2020 but is still subject to certain conditions.
Mr. Plaggemars was appointed non-executive director of Wiluna Mining
Corporation, an Australian incorporated gold producing company listed on the
ASX listed, in July 2021. Following a change of management and a review of the
company’s financial position, the board identified a significant funding
deficit and made the decision to put the company into voluntary
administration. The company is currently still in administration.
Mr. Plaggemars indirectly holds 6,667 Ordinary Shares, equating to
approximately 0.04 per cent. of the Company’s enlarged issued share capital
on Admission, but no options or warrants over Ordinary Shares. There is no
further information regarding Mr. Plaggemars that is required to be disclosed
under the AIM Rules
Appendix 2 – PDMR Disclosures
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1 Details of the person discharging managerial responsibilities/person closely associated
a. Name Heikki Lanckriet
2 Reason for notification
a. Position/Status Director
b. Initial notification/ Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a. Name 4basebio PLC
b. LEI 213800E2DX9EAIUNCB30
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a. Description of the financial instrument, type of instrument Ordinary shares of EUR1 each GB00BMCLYF79
Identification Code
b. Nature of the transaction Sale of shares pursuant to the Secondary Sale.
c. Price(s) and volume(s)
Price(s) Volume(s)
1,500p 315,706
d. Aggregated information Price(s) – 1,500p Volume(s) - 315,706
e. Date of the transaction 13 November 2024
f. Place of the transaction London, UK
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1 Details of the person discharging managerial responsibilities/person closely associated
a. Name David Roth
2 Reason for notification
a. Position/Status Director
b. Initial notification/ Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a. Name 4basebio PLC
b. LEI 213800E2DX9EAIUNCB30
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a. Description of the financial instrument, type of instrument Ordinary shares of EUR1 each GB00BMCLYF79
Identification Code
b. Nature of the transaction Sale of shares pursuant to the Secondary Sale.
c. Price(s) and volume(s)
Price(s) Volume(s)
1,500p 101,834
d. Aggregated information Price(s) – 1,500p Volume(s) - 101,834
e. Date of the transaction 13 November 2024
f. Place of the transaction London, UK
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1 Details of the person discharging managerial responsibilities/person closely associated
a. Name Dr. Amy Walker
2 Reason for notification
a. Position/Status Director
b. Initial notification/ Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a. Name 4basebio PLC
b. LEI 213800E2DX9EAIUNCB30
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a. Description of the financial instrument, type of instrument Ordinary shares of EUR1 each GB00BMCLYF79
Identification Code
b. Nature of the transaction Sale of shares pursuant to the Secondary Sale.
c. Price(s) and volume(s)
Price(s) Volume(s)
1,500p 11,459
d. Aggregated information Price(s) – 1,500p Volume(s) - 11,459
e. Date of the transaction 13 November 2024
f. Place of the transaction London, UK
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1 Details of the person discharging managerial responsibilities/person closely associated
a. Name Joseph Fernández
2 Reason for notification
a. Position/Status Director
b. Initial notification/ Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a. Name 4basebio PLC
b. LEI 213800E2DX9EAIUNCB30
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a. Description of the financial instrument, type of instrument Ordinary shares of EUR1 each GB00BMCLYF79
Identification Code
b. Nature of the transaction Sale of shares pursuant to the Secondary Sale.
c. Price(s) and volume(s)
Price(s) Volume(s)
1,500p 95,916
d. Aggregated information Price(s) – 1,500p Volume(s) - 95,916
e. Date of the transaction 13 November 2024
f. Place of the transaction London, UK
Copyright (c) 2024 PR Newswire Association,LLC. All Rights ReservedRecent news on 4Basebio
See all newsREG-4basebio Plc: Director Dealing
AnnouncementREG-4basebio Plc: 4basebio Receives GMP Licence for its UK DNA Manufacturing Facility
AnnouncementREG-4basebio Plc: Holding(s) in Company
AnnouncementREG-4basebio Plc: RBC Capital Markets initiates research coverage
AnnouncementREG - AIM - AIM Notice - 11/03/2025
Announcement